Global biotech company CSL has commenced manufacturing the University of Oxford/AstraZeneca AZD1222 COVID-19 vaccine candidate at its unique advanced manufacturing facility in Broadmeadows, in the north west of Melbourne.
CSL has separate contracts with AstraZeneca and the Australian Government to manufacture approximately 30 million doses of the AZD1222 vaccine candidate, with first doses planned for release in the first half of 2021, pending the outcome of clinical trials and regulatory approval.
During 2020/2021, the company will manufacture eight large scale batches of vaccine drug substance to ensure Australians have access to the vaccine should the vaccine demonstrate its safety and efficacy in clinical trials that are currently underway. It is anticipated that it will require a two dose per person regime.
The start of manufacturing is a further endorsement of Melbourne’s world leading biotechnology sector and our advanced manufacturing capabilities.
Melbourne is home to one of the world's largest biotechnology clusters, consisting of global and homegrown companies known for their excellence and innovation.
It offers a culture of innovation, highly skilled talent, cutting edge research & development infrastructure, and advanced manufacturing expertise.
More than 40% of Australian-based biotechnology and medical technology companies have made their homes in Melbourne and the sector generates global revenue of over A$20 billion and employs around 31,400 people.
To explore opportunities for collaborating with Melbourne’s biotechnology sector, contact us.
